A Phase III, Multicentre Study to Evaluate Consolidation Treatment With AZD0120 Compared With ASCT, in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible (DURGA-6).

NCT07735637 · clinicaltrials.gov ↗

PHASE3

Phase

NOT_YET_RECRUITING

Status

750

Enrollment

INDUSTRY

Sponsor class

Conditions

Newly Diagnosed Multiple Myeloma (NDMM)

Interventions

BIOLOGICAL: AZD0120
DRUG: Cyclophosphamide
DRUG: Fludarabine
DRUG: Melphalan (part of ASCT)
DRUG: Lenalidomide

Sponsor

AstraZeneca